Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Anixa Biosciences, Inc.NASDAQ: ANIX
EPS (Basic) · Q2 FY2026 · quarter ended Apr 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$0.07, compared with -$0.09 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.3.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 1 analysts of -$0.31 (+7.8%) for the fiscal year ending Oct 2026, a slowdown from the +12.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -$0.07+9.3% QoQ
- Last fiscal yearOct 2025
- -$0.34+12.8% YoY
- LTMApr 2026
- -$0.3-2157.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.2% | -17.7% | -36.9 pp |
| 1 year | +12.8% | +7.8% | -5.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.34) USD
- Year-over-year change
- +12.8%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (0.34) | +12.8% |
| FY2024 | 2024-10-31 | (0.39) | -21.9% |
| FY2023 | 2023-10-31 | (0.32) | +28.9% |
| FY2022 | 2022-10-31 | (0.45) | +0.0% |
| FY2021 | 2021-10-31 | (0.45) | — |
EPS (Basic) vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 EPS (Basic) of -$0.3 is the 4th highest of the 10 companies compared; the peer median is -$0.99.
- Its year-over-year change of -2157.2% is the lowest of 10, against a peer median of +45.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $1.73 | +120.0% | — | |
| LTM Mar 2026 | $0.27 | +120.9% | — | |
| LTM Mar 2026 | -$0.26 | -164.2% | — | |
| LTM Apr 2026 | -$0.3 | -2157.2% | — | |
| LTM Mar 2026 | -$0.61 | +87.1% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$0.99 | +45.3% | — |
| LTM Mar 2026 | -$1.24 | +10.8% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$1.31 | +32.5% | — |
| LTM Mar 2026 | -$1.71 | +99.8% | — | |
| LTM Mar 2026 | -$1.87 | +3.6% | — | |
| Peer median (excluding ANIX) | -$0.99 | +45.3% | — | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 512K | 0 | 210K | 0 | 0 |
| Cost of Revenue | 385K | 0 | 161K | 0 | 36K |
| Gross Profit | 127K | 0 | 49K | 0 | (36K) |
| Gross Margin | 24.8% | — | 23.3% | — | — |
| Research & Development | 6.19M | 6.7M | 4.77M | 6.4M | 5.07M |
| Selling, General & Admin | 7.07M | 7.17M | 6.29M | 7.44M | 6.63M |
| Operating Expenses | 13.26M | 13.88M | 11.06M | 13.83M | 11.67M |
| Depreciation & Amortization | 59.86K | 42K | 46K | 37K | 36K |
| EBITDA | (13.08M) | (13.73M) | (9.88M) | (12.66M) | (10.99M) |
| EBITDA Margin | -2554.9% | — | -4706.7% | — | — |
| Operating Income | (13.14M) | (13.88M) | (11.01M) | (13.83M) | (11.7M) |
| Operating Margin | -2565.6% | — | -5243.3% | — | — |
| Interest Income | 2.32K | 104K | 1.08M | 1.13M | 673K |
| Interest Expense | 322 | 104K | 0 | 0 | 0 |
| Other Income / Expenses | 7.77K | 104K | 1.08M | 1.13M | 673K |
| Income Before Tax | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Pre-Tax Margin | -2564.0% | — | -4728.6% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.95M) | (13.6M) | (9.81M) | (12.55M) | (10.93M) |
| Net Margin | -2528.6% | — | -4671.9% | — | — |
| EPS (Basic) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| EPS (Diluted) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| Weighted Avg Shares | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
| Weighted Avg Shares (Diluted) | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.